EpiVax, Inc. Subsidiary, EpiVax Therapeutics Signs Exclusive Collaboration Agreement with GreenLight Biosciences to Develop Personalized Cancer Vaccines

EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products

Publication: H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

Publication: In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines.

Discover

We take pride in our ability to put our combined intelligence, experience, and creativity to work to improve human health. Open minds, creative thought and natural curiosity lead to paradigm shifts. Contact us today to learn more.

Corporate Office/Laboratory:
EpiVax, Inc.
188 Valley Street, Suite 424, Providence, RI 02909 USA
ph: 401.272.2123 fax: 401.272.7562

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here